LifeStance Health Group, Inc. (NASDAQ:LFST) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• LifeStance Health Group, Inc. has an average analyst rating of "Moderate Buy" with seven brokerages covering the stock, which includes five buy recommendations and one strong buy.
• The stock opened at $5.48 and has experienced significant trading activity, including a notable sale of over 8 million shares by a director.
• The company reported its earnings with a 10.6% year-over-year revenue increase, exceeding analyst expectations for both revenue and earnings per share.

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $8.50.

Several equities analysts have weighed in on the stock. BTIG Research assumed coverage on shares of LifeStance Health Group in a report on Friday, July 25th. They set a "buy" rating and a $8.00 price target on the stock. Wall Street Zen upgraded shares of LifeStance Health Group from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, UBS Group lifted their price objective on shares of LifeStance Health Group from $8.50 to $9.00 and gave the company a "buy" rating in a research report on Friday, August 8th.

LifeStance Health Group Stock Down 3.5%

Shares of LifeStance Health Group stock traded down $0.20 during trading on Friday, hitting $5.44. The company's stock had a trading volume of 743,257 shares, compared to its average volume of 2,012,021. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.48 and a current ratio of 1.48. The company has a fifty day simple moving average of $4.74 and a two-hundred day simple moving average of $5.87. The company has a market capitalization of $2.11 billion, a PE ratio of -108.90 and a beta of 1.17. LifeStance Health Group has a 52 week low of $3.74 and a 52 week high of $8.61.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.02. The company had revenue of $345.31 million during the quarter, compared to analyst estimates of $345.05 million. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.11%. LifeStance Health Group's quarterly revenue was up 10.6% compared to the same quarter last year. During the same period last year, the business earned ($0.06) EPS. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts predict that LifeStance Health Group will post -0.18 earnings per share for the current year.

Insider Activity

In other LifeStance Health Group news, Director Darren M. Black sold 8,407,643 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the transaction, the director owned 33,524,715 shares in the company, valued at $169,970,305.05. The trade was a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Summit Partners L. P sold 8,407,643 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the sale, the insider directly owned 33,524,715 shares of the company's stock, valued at $169,970,305.05. This represents a 20.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,423,643 shares of company stock worth $103,561,790. 6.60% of the stock is currently owned by insiders.

Institutional Trading of LifeStance Health Group

Large investors have recently made changes to their positions in the stock. DekaBank Deutsche Girozentrale purchased a new stake in LifeStance Health Group in the first quarter worth about $31,000. Bayesian Capital Management LP purchased a new stake in shares of LifeStance Health Group during the second quarter valued at about $52,000. Park Edge Advisors LLC purchased a new stake in shares of LifeStance Health Group during the second quarter valued at about $52,000. Xponance Inc. purchased a new stake in shares of LifeStance Health Group during the first quarter valued at about $69,000. Finally, Ameriprise Financial Inc. purchased a new stake in shares of LifeStance Health Group during the fourth quarter valued at about $87,000. 85.50% of the stock is owned by hedge funds and other institutional investors.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.